CA2366552A1 - Detection d'une activite superantigenique dans un echantillon biologique - Google Patents

Detection d'une activite superantigenique dans un echantillon biologique Download PDF

Info

Publication number
CA2366552A1
CA2366552A1 CA002366552A CA2366552A CA2366552A1 CA 2366552 A1 CA2366552 A1 CA 2366552A1 CA 002366552 A CA002366552 A CA 002366552A CA 2366552 A CA2366552 A CA 2366552A CA 2366552 A1 CA2366552 A1 CA 2366552A1
Authority
CA
Canada
Prior art keywords
cells
beta
expansion
molecules
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366552A
Other languages
English (en)
French (fr)
Inventor
Herve Perron
Monique Lafon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9903622A external-priority patent/FR2791139B1/fr
Application filed by Individual filed Critical Individual
Publication of CA2366552A1 publication Critical patent/CA2366552A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002366552A 1999-03-19 2000-03-20 Detection d'une activite superantigenique dans un echantillon biologique Abandoned CA2366552A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR99/03622 1999-03-19
FR9903622A FR2791139B1 (fr) 1999-03-19 1999-03-19 Procede de detection d'une activite superantigenique dans un echantillon biologique
FR99/13755 1999-10-28
FR9913755A FR2791140B1 (fr) 1999-03-19 1999-10-28 Procede de detection d'une activite superantigenique dans un echantillon et composition therapeutique ou prophylactique
PCT/FR2000/000691 WO2000057185A1 (fr) 1999-03-19 2000-03-20 Detection d'une activite superantigenique dans un echantillon biologique

Publications (1)

Publication Number Publication Date
CA2366552A1 true CA2366552A1 (fr) 2000-09-28

Family

ID=26234877

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366552A Abandoned CA2366552A1 (fr) 1999-03-19 2000-03-20 Detection d'une activite superantigenique dans un echantillon biologique

Country Status (10)

Country Link
US (1) US20060088820A1 (https=)
EP (1) EP1163522B1 (https=)
JP (1) JP2002539804A (https=)
AT (1) ATE346299T1 (https=)
AU (1) AU3437700A (https=)
CA (1) CA2366552A1 (https=)
DE (1) DE60031963T2 (https=)
ES (1) ES2276675T3 (https=)
FR (1) FR2791140B1 (https=)
WO (1) WO2000057185A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148323A2 (en) * 2009-06-18 2010-12-23 Whittemore Peterson Institute For Neuro-Immune Disease Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
US20110151431A1 (en) * 2009-06-18 2011-06-23 Whittemore Peterson Institute For Neuro-Immune Disease Detection of xenotropic murine leukemia virus
US20110117056A1 (en) * 2009-06-18 2011-05-19 Whittemore Peterson Institute For Neuro-Immune Disease Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
US20100167268A1 (en) * 2009-07-15 2010-07-01 Mikovits Judy A Seroconversion assays for detecting xenotropic murine leukemia virus-related virus
EP2949342A1 (en) * 2014-05-28 2015-12-02 Geneuro SA Antiretroviral drug targeting human endogenous retrovirus
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
FR2765588A1 (fr) * 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques

Also Published As

Publication number Publication date
DE60031963D1 (de) 2007-01-04
JP2002539804A (ja) 2002-11-26
FR2791140A1 (fr) 2000-09-22
US20060088820A1 (en) 2006-04-27
WO2000057185A1 (fr) 2000-09-28
ES2276675T3 (es) 2007-07-01
EP1163522A1 (fr) 2001-12-19
FR2791140B1 (fr) 2002-03-22
ATE346299T1 (de) 2006-12-15
AU3437700A (en) 2000-10-09
DE60031963T2 (de) 2007-06-14
EP1163522B1 (fr) 2006-11-22

Similar Documents

Publication Publication Date Title
EP1203239B1 (fr) Utilisation d'un polypeptique pour detecter un etat pathologique associe a la sclerose en plaques
Quintana et al. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation
JP3445917B2 (ja) 抗原特異的活性化t細胞
TW202043255A (zh) 具增進氧化還原酶基序之免疫原肽
EP1861418B1 (fr) Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
US10858422B2 (en) Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP4987698B2 (ja) 癌関連抗原アナログペプチド、およびその利用
JPH10501791A (ja) クラスimhcペプチドによる細胞傷害性t細胞リンパ球(「ctl」)活性の調節
EP1163522B1 (fr) Detection d'une activite superantigenique induite par msrv-1 dans un echantillon biologique
WO1991012332A1 (fr) Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite
FR2830940A1 (fr) Procede de selection de ligands d'hla-dp4 et ses applications
EP1697502A2 (fr) Methodes d identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
FR2865403A1 (fr) Composition pour le traitement d'une pathologie associee a la msrv/herv-w
CA2616565A1 (fr) Utilisation d'un polypeptique pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
FR2841786A1 (fr) Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
FR2841787A1 (fr) Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
WO2002035242A1 (fr) Procede d'identification de nouvelles molecules se liant au recepteur lox
FR2850384A1 (fr) Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
KR0167016B1 (ko) 항원 특이적인 활성화된 t 림프구, 이것의 검출 및 사용방법
FR2816059A1 (fr) Procede d'identification de nouvelles molecules se liant aux recepteurs scavenger et signalees via un recepteur toll
HK40112339A (zh) 靶向sars-cov-2抗原的肽和工程化t细胞受体及其使用方法
EP3765053A2 (en) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
FR2736831A1 (fr) Sequences nucleotidiques et peptidiques pour le traitement de la myasthenie
FR2791139A1 (fr) Procede de detection d'une activite superantigenique dans un echantillon biologique

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued